基本數據
| CIK | 1584371 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IceCure Medical Ltd
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of: June 2026 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| June 2, 2026 |
Exhibit 99.1 IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance Proactive Step to Regain Nasdaq Compliance as Part of the Company’s Broader Capital Markets Strategy CAESAREA, ISRAEL, June 2, 2026 (PR NEWSWIRE) - IceCure Medical Ltd. (the “Company” or “IceCure” or “IceCure Medical”) (Nasdaq: ICCM), developer of minimally-invasive cryoablation technology that destroy |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2026 (Report No. 6) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| May 19, 2026 |
Exhibit 99.1 IceCure’s ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free a |
|
| May 13, 2026 |
Exhibit 99.1 IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares CAESAREA, Israel, May 13, 2026 - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as a |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2026 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2026 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| May 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2026 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| May 12, 2026 |
ICECURE MEDICAL LTD. ORDINARY SHARES SALES AGREEMENT Exhibit 10.1 ICECURE MEDICAL LTD. ORDINARY SHARES SALES AGREEMENT May 12, 2026 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: IceCure Medical Ltd., a company incorporated under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sa |
|
| May 12, 2026 |
Exhibit 99.1 IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance Accelerating adoption of ProSense® driven by several growth catalyst |
|
| May 12, 2026 |
Up to $4,339,697 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-290046 Prospectus Supplement (To Prospectus dated March 24, 2026) Up to $4,339,697 Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P. or the Sales Agent, dated as of May 12, 2026, relating to the sale of our ordinary shares, no par value per share, or Ordinary Shares, |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of p |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execut |
|
| April 22, 2026 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on Monday, May 11, 2026 at 5:00 p.m. Israel time, or at any adjournment or postponement thereof, by means of remote communication at the following link: https://teams.microsoft.com/meet/33524497399082?p |
|
| April 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2026 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| April 22, 2026 |
Exhibit 99.2 ICECURE MEDICAL LTD. CAESAREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 11, 2026 This proxy statement (the “Proxy Statement”) is being solicited by our board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s Special General Meeting of Shareholders (the “Meeting”) to be held on Monday, May 11 |
|
| April 22, 2026 |
ICECURE MEDICAL LTD. FORM OF PROXY CARD THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. FORM OF PROXY CARD THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, and Ms. Rotem Naim, Director of Finance, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the ordin |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| April 21, 2026 |
Exhibit 99.1 IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025 The Company’s participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates Cryoablation cost analysis study from Massachusetts General Hos |
|
| April 8, 2026 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel April 8, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: IceCure Medical Ltd. (CIK 0001584371) Registration Statement on Form F-1 (File No. 333-294827) (the “Registration Statement”) Request for Ac |
|
| April 6, 2026 |
April 6, 2026 Eyal Shamir Chief Executive Officer IceCure Medical Ltd. 7 Ha Eshel St., PO Box 3163 Caesarea, 3079504 Israel Re: IceCure Medical Ltd. Registration Statement on Form F-1 Filed April 1, 2026 File No. 333-294827 Dear Eyal Shamir: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acce |
|
| April 1, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 IceCure Medical Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, |
|
| April 1, 2026 |
As filed with the Securities and Exchange Commission on April 1, 2026 As filed with the Securities and Exchange Commission on April 1, 2026 Registration No. |
|
| March 27, 2026 |
SERIES C ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 27, 2026 |
SERIES B ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 27, 2026 |
[The remainder of this page has been intentionally left blank.] Exhibit 10.2 March 26, 2026 IceCure Medical Ltd. Attn: Eyal Shamir, Chief Executive Officer 7 Ha’Eshel St., PO Box 3163 Casarea, 3079504 Israel Dear Mr. Shamir: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), that the Placement |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 8) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| March 27, 2026 |
Form OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 Form OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 26, 2026, between IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHER |
|
| March 27, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-290046 Prospectus Supplement (To Prospectus dated March 24, 2026) 8,000,000 Ordinary Shares We are offering to certain investors under a securities purchase agreement dated March 26, 2026 between us and certain investors, in a registered direct offering, or the offering, 8,000,000 of our ordinary shares, no par value per share, or the Ordinary |
|
| March 27, 2026 |
Exhibit 99.1 IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement CAESAREA, Israel, March 26, 2026 /PRNewswire/ - IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 7) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| March 25, 2026 |
Exhibit 99.1 IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of results to be presented at European Conference of Interv |
|
| March 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 6) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| March 24, 2026 |
Exhibit 99.1 IceCure Appoints Meir Peleg as Chief Financial Officer Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoab |
|
| March 23, 2026 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel March 23, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: IceCure Medical Ltd. (CIK 0001584371) Registration Statement on Form F-3 (File No. 333-290046) (the “Registration Statement”) Request for A |
|
| March 20, 2026 |
As filed with the Securities and Exchange Commission on March 20, 2026 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No. |
|
| March 20, 2026 |
As filed with the Securities and Exchange Commission on March 20, 2026 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No. |
|
| March 17, 2026 |
Exhibit 99.1 IceCure Reports 2025 Full Year Financial & Operational Results Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectively Strong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast cancer and medical society recommendations 30 hybrid commercial-clinical sites to be added for FDA approved post-marketing study |
|
| March 17, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Tsimerman, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| March 17, 2026 |
IceCure Medical Ltd. Insider Trading Policy Effective January 12, 2022 Amended March 16, 2026 Exhibit 11.1 IceCure Medical Ltd. Insider Trading Policy Effective January 12, 2022 Amended March 16, 2026 I. Introduction This policy determines acceptable transactions in the securities of IceCure Medical Ltd. (the “Company”) by our employees, directors, consultants and other related persons. This policy arises from the Company’s status as a public company whose shares are traded on the Nasdaq C |
|
| March 17, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 17, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Eyal Shamir, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 17, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2025 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 17, 2026 |
Exhibit 2.1 Description of Share Capital The following description of IceCure Medical Ltd. (the “Company”) share capital, provisions of our amended and restated articles of association (“Articles”) as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as wel |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2026 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 17, 2026 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statements Nos. 333-290046 and 333-258660 on Form F-3, and Nos. 333-270982, 333-264578, 333-262620, and 333-281587 on Form S-8 of our report dated March 17, 2026, relating to the financial statements of IceCure Medical Ltd. appearing in this Annual Report on Form 20-F |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 17, 2026 |
Exhibit 4.3 IceCure Medical Ltd. (“the Company”) Compensation Policy for Company’s Office Holders Dated: May 2025 Introduction 1.1 Pursuant to the provisions of the Companies Law, 5759-1999 together with the regulations promulgated thereunder, all as amended from time to time (hereafter the – “Companies Law”), on January 18, 2022, the Company’s Compensation Committee (the “Compensation Committee”) |
|
| March 16, 2026 |
As filed with the Securities and Exchange Commission on March 16, 2026 As filed with the Securities and Exchange Commission on March 16, 2026 Registration No. |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2026 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 11, 2026 |
Exhibit 99.1 U.S. FDA Approves IceCure’s Post-Marketing “ChoICE” Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense® Clinical study sites may offer ProSense® cryoablation to additional patients not enrolled in the stud |
|
| March 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2026 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 9, 2026 |
Exhibit 99.1 American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer IceCure’s ICE3 study and the FDA Advisory Panel’s favorable vote on ProSense® cryoablation’s benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update New medical society guidance expected to further accelerate commercial |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2026 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exe |
|
| March 2, 2026 |
Exhibit 99.1 IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation Findings may impact treatment guidelines issued by medical societies for large non-cancerous breast tumors; study is believed t |
|
| February 23, 2026 |
Exhibit 99.1 IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate Incidence of kidney cancer is growing worldwide, with an estimated |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2026 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2026 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| February 9, 2026 |
Exhibit 99.1 IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, February 9, 2026 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an |
|
| January 12, 2026 |
Exhibit 99.1 IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatment of low-risk breast cancer, addressing a market opportunity of approximately 200,000 patients Record European |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2026 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 9, 2026 |
FIRST AMENDMENT TO EQUITY DISTRIBUTION agreement Exhibit 10.1 FIRST AMENDMENT TO EQUITY DISTRIBUTION agreement This FIRST AMENDMENT TO EQUITY DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of January 8, 2026, by and between IceCure Medical Ltd., a company formed under the laws of the State of Israel (the “Company”), and Maxim Group LLC (the “Agent”). WHEREAS, the Company and the Agent entered into an Equity Distribution Agreement, |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal ex |
|
| January 8, 2026 |
Exhibit 99.1 AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ICECURE MEDICAL LTD. (The “Company”) TABLE OF CONTENTS Article Subject Page 1. Preamble 1 2. Public company 2 3. Donations 2 4. Company’s objectives 2 5. Limitation of liability 2 6. Modification of these Articles 2 7. Share capital 2 8. Issue of shares and other securities 3 9. Company’s register of shareholders and issue of share certi |
|
| December 17, 2025 |
Exhibit 99.1 IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States CAESAREA, Israel, December 17, 2025 – IceCure Medical Ltd. ( |
|
| December 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| December 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| December 10, 2025 |
Exhibit 99.1 IceCure’s ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense® CAESAREA, Israel, December 10, 2025 – IceCure Medical Ltd. (Nasdaq |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| December 5, 2025 |
Exhibit 99.1 IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes Cryogenic flow control enhances the efficacy and precision of cryoablation procedures Robust IP portfolio becomes increasingly strategic as global interest in IceCure’s platform and next-generation cryoablation technologies grows following ProSense®’s recent |
|
| December 3, 2025 |
ICECURE MEDICAL LTD. FORM OF PROXY CARD THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. FORM OF PROXY CARD THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, Mr. Ronen Tsimerman, Chief Financial Officer, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the |
|
| December 3, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON WEDNESDAY, JANUARY 7, 2026 This proxy statement (the “Proxy Statement”) is being solicited by our board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s Special General Meeting of Shareholders (the “Meeting”) to be held on |
|
| December 3, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on Wednesday, January 7, 2026 at 17:00 Israel time, or at any adjournment or postponement thereof, by means of remote communication at the following link: https://eu-central-1.protection.sophos.com/?d=m |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| November 19, 2025 |
Exhibit 99.1 IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast cancer Demand for ProSense® systems expected to accelerate in 2026 Total U.S. population of approximately 200,000 patients, includes wom |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| November 18, 2025 |
Exhibit 99.1 IceCure’s ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer This latest approval further broadens global access to ProSense® and supports IceCure’s commercial momentum following the U.S. Food and Drug Administration’s (“FDA”) recent marketing authorization of ProSense® in low-risk breast cancer CA |
|
| November 14, 2025 |
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification CAESAREA, ISRAEL, November 14, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a written notice (the “Notice”) from Nasdaq Stock Marke |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| November 10, 2025 |
Exhibit 99.1 IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction Mr. Levav’s appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense® CAESAREA, Israel, November 10 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medic |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| November 3, 2025 |
Exhibit 99.1 IceCure’s Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival 5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone SBRT followed by cryoablation prod |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| October 3, 2025 |
Exhibit 99.1 IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above · ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer · Major advancement and new paradigm in breast cancer care as a simple, minimally invasive out-patient procedure |
|
| October 3, 2025 |
Exhibit 99-2 IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care · ProSense® cryoablation offers the choice of a minimally invasive outpatient procedure that destroys tumors by freezing without surgical removal of breast tis |
|
| September 30, 2025 |
Exhibit 99.1 IceCure’s ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented IceCure’s exclusive workshop was filled to capacity – Unlocking De-Escalation of Care: Cryoablation for Breast Cancer led by Key Opinion Leaders Dr. Federica Di Naro and Dr. Lucía Graña-Lopez 5 abstracts pr |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 (Report No. 6) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 25, 2025 |
X0101 EFFECT 33 LIVE 2025-09-25 0001213900-25-089524 POS AM 0001584371 IceCure Medical Ltd. 333-288062 |
|
| September 22, 2025 |
Exhibit 99.1 IceCure’s ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on endometriosis 3 hands-on training sessions for doctors interested in using ProSense® were very well attended Dedicated CIR |
|
| September 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 19, 2025 |
As filed with the Securities and Exchange Commission on September 19, 2025 As filed with the Securities and Exchange Commission on September 19, 2025 Registration No. |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 18, 2025 |
Exhibit 99.1 IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience XSense™ System with Cryoprobes recently received regulatory approval in the U.S. and Israel CAESAREA, Israel, September 18, 2025 – IceCure |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 15, 2025 |
Exhibit 99.1 IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications Approved for a broad range of indications including in gynecology, oncology and general surgery CAESAREA, Israel, September 15, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invas |
|
| September 9, 2025 |
September 9, 2025 Ronen Tsimerman Chief Financial Officer IceCure Medical Ltd. 7 Ha Eshel St., PO Box 3163 Caesarea, 3079504 Israel Re: IceCure Medical Ltd. Registration Statement on Form F-3 Filed September 4, 2025 File No. 333-290046 Dear Ronen Tsimerman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding r |
|
| September 4, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 IceCure Medical Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| September 4, 2025 |
As filed with the Securities and Exchange Commission on September 4, 2025 As filed with the Securities and Exchange Commission on September 4, 2025 Registration No. |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| September 4, 2025 |
Exhibit 99.1 IceCure’s ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in the European Union for gynecological indications CAESAREA, Israel, September 4, 202 |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 (Report No. 3) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 13, 2025 |
Exhibit 99.3 IceCure Reports Financial & Operational Results for the First Half of 2025 $10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, August 13, 2025 – IceCure Medical Ltd. |
|
| August 13, 2025 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 13, 2025 |
Exhibit 99.1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) As of June 30, As of December 31, 2025 2024 ASSETS CURRENT ASSETS Cash and cash equivalents 5,383 7,564 Trade receivables 122 221 Inventory 2,329 1,988 Prepaid expenses and other receivables 1,186 981 Total current assets 9,020 10,754 NON-CURREN |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal ex |
|
| August 1, 2025 |
As filed with the Securities and Exchange Commission on August 1, 2025 As filed with the Securities and Exchange Commission on August 1, 2025 Registration No. |
|
| August 1, 2025 |
Exhibit 99.1 IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million CAESAREA, Israel, July 29, 2025 /PRNewswire/ - IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to |
|
| August 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of August 2025 Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| August 1, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 1, 2025 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Monday |
|
| August 1, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on at, or at any adjournment or postponement thereof, by means of remote communication at the following link: https://teams.microsoft.com/dl/launcher/launcher.html?url=%2F%23%2Fl%2Fmeetup-join%2F19% 3Am |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of July 2025 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 28, 2025 |
Prospectus Supplement No. 2 (To Prospectus dated July 9, 2025, as supplemented by Prospectus Supplement No. 1, dated July 16, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-288062 ICECURE MEDICAL LTD. An Aggregate of $10,000,000 in Non-Transferable Subscription Rights to purchase up to 10,000,000 Units, at a Subscription Price of $1.00 per Unit, consisting of an aggregate of |
|
| July 28, 2025 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, Mr. Ronen Tsimerman, Chief Financial Officer, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the ordinary shar |
|
| July 28, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on at, or at any adjournment or postponement thereof, by means of remote communication at the following link: Join the meeting now At the Meeting, shareholders will be asked to consider and vote on the |
|
| July 28, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 1, 2025 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Monday |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 25, 2025 |
Exhibit 99.1 IceCure’s ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 202 |
|
| July 16, 2025 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Director, Mr. Ronen Tsimerman, Chief Financial Officer, and each of them, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all th |
|
| July 16, 2025 |
ICECURE MEDICAL Ltd. Notice of Annual and SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholder: We cordially invite you to attend the Annual and Special General Meeting of Shareholders (the “Meeting”) of IceCure Medical Ltd. (the “Company”), to be held on Wednesday, August 20, 2025 at 18:30 Israel time, or at any adjournment or postponement thereof, by means of remote communication at the following link: Join the meeting now https://eu-cent |
|
| July 16, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT ANNUAL AND SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 20, 2025 This proxy statement (the “Proxy Statement”) is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s annual and special general meeting of shareholders (the “Meeting”) to |
|
| July 16, 2025 |
Prospectus Supplement (To Prospectus dated July 9, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the Month of July 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| July 10, 2025 |
IceCure Announces Commencement of Rights Offering Exhibit 99.1 IceCure Announces Commencement of Rights Offering CAESAREA, Israel, July 10, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has commenced its previously disclosed rights offering (the |
|
| July 9, 2025 |
Prospectus Filed Pursuant to Rule 424(b)(3) Registration No. 333-288062 IceCure Medical Ltd. An Aggregate of $10,000,000 in Non-Transferable Subscription Rights to purchase up to 10,000,000 Units, at a Subscription Price of $1.00 per Unit, consisting of an aggregate of up to 10,000,000 Ordinary Shares and Warrants to purchase up to 10,000,000 Ordinary Shares 10,000,000 Units, at a Subscription Pri |
|
| July 7, 2025 |
As filed with the Securities and Exchange Commission on July 7, 2025 As filed with the Securities and Exchange Commission on July 7, 2025 Registration No. |
|
| July 3, 2025 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel July 3, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: IceCure Medical Ltd. (CIK 0001584371) Registration Statement No. 333-288062 on Form F-1 (the “Registration Statement”) Ladies and Gentlemen: IceCure Medical Ltd. (the “Registrant”) hereby requ |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: July 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| July 3, 2025 |
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 Exhibit 99.1 IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 CAESAREA, Israel, July 3, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary financial re |
|
| July 3, 2025 |
As filed with the Securities and Exchange Commission on July 3, 2025 As filed with the Securities and Exchange Commission on July 3, 2025 Registration No. |
|
| June 25, 2025 |
Exhibit 10.12 ICECURE MEDICAL LTD. and Vstock Transfer, LLC, as Warrant Agent Form of Warrant Agency Agreement Dated as of , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2025 (“Agreement”), by and between IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and VStock Transfer, LLC (“VStock” or the “Warrant Agent”). W I T N E S S |
|
| June 25, 2025 |
As filed with the Securities and Exchange Commission on June 25, 2025 As filed with the Securities and Exchange Commission on June 25, 2025 Registration No. |
|
| June 25, 2025 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.3 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| June 25, 2025 |
FORM OF ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.2 FORM OF ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2025 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial |
|
| June 25, 2025 |
Exhibit 4.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN ICECURE MEDICAL, LTD.’S PROSPECTUS DATED [●], 2025 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE INFORMATION AGENT, BY TELEPHONE ((888) 789-8409) OR EMAIL ([email protected]). IceCure Medical Lt |
|
| June 25, 2025 |
IceCure Announces Record Date for Rights Offering for Up to $10 Million Exhibit 99.1 IceCure Announces Record Date for Rights Offering for Up to $10 Million CAESAREA, Israel, June 25, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights |
|
| June 25, 2025 |
Exhibit 99.6 NOMINEE HOLDER CERTIFICATION The undersigned, a broker, dealer, custodian bank, trustee, depositary or other nominee holder of subscription rights (the “Rights”) to purchase Units (each, a “Unit”) consisting of one ordinary share, no par value per share (“Ordinary Share”) and one warrant to purchase one Ordinary Share (the “Warrant”) of IceCure Medical Ltd. (the “Company”), pursuant t |
|
| June 25, 2025 |
Exhibit 99.4 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEES ICECURE MEDICAL LTD. NON-TRANSFERABLE RIGHTS TO PURCHASE UP TO 10,000,000 UNITS, REPRESENTING UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES OR PRE-FUNDED WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES THE RIGHTS ARE EXERC |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| June 25, 2025 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Dated June 25, 2025 Relating to Preliminary Prospectus, dated June 25, 2025 Registration No. |
|
| June 25, 2025 |
ICECURE MEDICAL LTD. FORM OF DEALER-MANAGER AGREEMENT Exhibit 1.1 ICECURE MEDICAL LTD. FORM OF DEALER-MANAGER AGREEMENT [●], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 As Dealer-Manager Ladies and Gentlemen: The following will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”) |
|
| June 25, 2025 |
Exhibit 99.3 FORM OF LETTER TO BROKERS AND OTHER NOMINEES ICECURE MEDICAL LTD. NON-TRANSFERABLE RIGHTS TO PURCHASE UP TO 10,000,000 UNITS, REPRESENTING UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES or PRE-FUNDED WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES THE RIGHTS ARE EXERCISABLE UNTI |
|
| June 25, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. NON-TRANSFERABLE RIGHTS TO PURCHASE UP TO 10,000,000 UNITS, REPRESENTING UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES or PRE-FUNDED WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES AND WARRANTS TO PURCHASE UP TO 10,000,000 ORDINARY SHARES THE RIGHTS ARE EXERCISABLE UNTIL 5:00 P.M., NEW YORK CITY TIME, ON JULY 28, |
|
| June 25, 2025 |
BENEFICIAL OWNER ELECTION FORM Exhibit 99.5 BENEFICIAL OWNER ELECTION FORM The undersigned acknowledge(s) receipt of your letter and the enclosed materials referred to therein relating to the distribution in a rights offering (the “Rights Offering”) by IceCure Medical Ltd. (the “Company”), to the holders of record (the “Record Holders”) of its ordinary shares, no par value per share (the “Ordinary Shares”), as of 5:00 p.m., New |
|
| June 25, 2025 |
Exhibit 99.1 INSTRUCTIONS AS TO USE OF ICECURE MEDICAL LTD.’s RIGHTS CERTIFICATE CONSULT THE INFORMATION AGENT, YOUR BANK OR BROKER AS TO ANY QUESTIONS The following instructions relate to the distribution of rights (the “Rights Offering”) by IceCure Medical Ltd., a company incorporated under the laws of the State of Israel (“Company”), to all holders of record (the “Record Holders”) of its ordina |
|
| June 16, 2025 |
As filed with the Securities and Exchange Commission on June 16, 2025 As filed with the Securities and Exchange Commission on June 16, 2025 Registration No. |
|
| June 16, 2025 |
SUBSCRIPTION AND INFORMATION AGENT AGREEMENT Exhibit 10.11 SUBSCRIPTION AND INFORMATION AGENT AGREEMENT This Subscription and Information Agent Agreement (the “Agreement”) is entered into as of this 19th day of May, 2025 (the “Effective Date”) by and between, IceCure Medical Ltd., organized and existing under the laws of the State of Israel (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, a Company having its principal office |
|
| June 16, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) IceCure Medical Ltd. |
|
| June 16, 2025 |
IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel IceCure Medical Ltd. 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel June 16, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: IceCure Medical Ltd. (CIK 0001584371) Registration Statement No. 333-282652 on Form F-1, as amended Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as |
|
| June 9, 2025 |
Exhibit 99.1 IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA’s marketing authorization decision in early-stage breast cancer CAESAREA, Israel, June 9, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Compa |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: June 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| May 28, 2025 |
Exhibit 99.1 IceCure Medical Reports First Quarter 2025 Financial Results Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Isr |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: May 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| May 23, 2025 |
As confidentially submitted to Securities and Exchange Commission on May 22, 2025. |
|
| May 21, 2025 |
Exhibit 10.1 UNSECURED LOAN AGREEMENT This Unsecured Loan Agreement (“Agreement”) is made and entered into as of May 17, 2025 (the “Effective Date”), by and between Icecure Medical Ltd. (the “Borrower”) and Epoch Partner Investments Limited (the “Lender”). WHEREAS, the Borrower requires funds in order to conduct its business activities, and for this purpose, it desires to borrow $2,000,000 from th |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 (Report No. 2) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of p |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal execut |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: April 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| April 30, 2025 |
Exhibit 99.1 IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer ● Final marketing authorization decision for early-stage breast cancer is expected upon the FDA’s approval of IceCure’s post-market study plan ● IceCure to engage with potential clinical sites, breast surgeons and r |
|
| April 10, 2025 |
ICECURE MEDICAL LTD. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Exhibit 99.3 ICECURE MEDICAL LTD. PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints, Mr. Eyal Shamir, Chief Executive Officer and Mr. Ronen Tsimerman, Chief Financial Officer, as agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the Ordinary Shares of IceC |
|
| April 10, 2025 |
Exhibit 99.2 ICECURE MEDICAL LTD. CEASEREA, ISRAEL PROXY STATEMENT SPECIAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2025 The enclosed proxy statement is being solicited by the board of directors (the “Board of Directors”) of IceCure Medical Ltd. (the “Company”) for use at the Company’s special general meeting of shareholders (the “Meeting”) to be held at on Thursday, May 15, 2025 at 1 |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-40753 ICECURE MEDICAL Ltd. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exec |
|
| April 10, 2025 |
ICECURE MEDICAL Ltd. Notice of SPECIAL General Meeting of shareholders Exhibit 99.1 Dear IceCure Medical Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of IceCure Medical Ltd. (the “Meeting”), to be held on Thursday, May 15, 2025 at 16:00 Israel time, or at any adjournment or postponement thereof, at the Company’s offices at 7 Ha’Eshel St., Caesarea, 3079504, Israel. At the Meeting, shareholders will be asked to consi |
|
| March 27, 2025 |
Exhibit 2.1 Description of Share Capital The following description of IceCure Medical Ltd. (the “Company”) share capital, provisions of articles of association (“Articles”) as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli law and |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No.5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of |
|
| March 27, 2025 |
IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 Exhibit 11.1 IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 I. Introduction This policy determines acceptable transactions in the securities of IceCure Medical Ltd. (the “Company”) by our employees, directors, consultants and other related persons. This policy arises from the Company’s status as a public company whose shares are traded on the Nasdaq |
|
| March 27, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statements Nos. 333-258660 and 333-267272 on Form F-3 and Nos. 333-262620, 333-264578, 333-270982, and 333-281587 on Form S-8 of our report dated March 27, 2025, relating to the consolidated financial statements of IceCure Medical Ltd. appearing in this Annual Report o |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Tsimerman, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| March 27, 2025 |
IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 Exhibit 11.1 IceCure Medical Ltd. Insider Trading Policy Effective January 12 , 2022 Amended March 26, 2025 I. Introduction This policy determines acceptable transactions in the securities of IceCure Medical Ltd. (the “Company”) by our employees, directors, consultants and other related persons. This policy arises from the Company’s status as a public company whose shares are traded on the Nasdaq |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Eyal Shamir, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Ronen Tsimerman, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstanc |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANTTO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| March 27, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statements Nos. 333-258660 and 333-267272 on Form F-3 and Nos. 333-262620, 333-264578, 333-270982, and 333-281587 on Form S-8 of our report dated March 27, 2025, relating to the consolidated financial statements of IceCure Medical Ltd. appearing in this Annual Report o |
|
| March 27, 2025 |
Exhibit 2.1 Description of Share Capital The following description of IceCure Medical Ltd. (the “Company”) share capital, provisions of articles of association (“Articles”) as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli law and |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Eyal Shamir, certify that: 1. I have reviewed this annual report on Form 20–F of IceCure Medical Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 27, 2025 |
Exhibit 99.1 IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Tim |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 27, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by IceCure Medical Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to my knowledge: (1) the Report fully complies with the |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 20, 2025 |
Exhibit 99.1 IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel, March 20, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation tech |
|
| March 18, 2025 |
Exhibit 99.1 IceCure’s ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference ● IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeons ● An abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster presentation gallery ● An independent study by Dr. Ava Kwong evalu |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 17, 2025 |
Exhibit 99.1 IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology This latest IP win rounds out protection for the cryogenic pump in major global market following grants for the same patent in the U.S., Europe and Japan CAESAREA, Israel, March 17, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”) |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| March 10, 2025 |
Exhibit 99.1 Breast Cancer Patients who Underwent IceCure’s ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery ● Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma ● Patients who underwent cryoablation compare |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: March 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal exe |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| February 24, 2025 |
Exhibit 99.1 IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand CAESAREA, Israel, February 24, 2025 – IceCure Medical Ltd. (Nasdaq: IC |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: February 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| February 4, 2025 |
Exhibit 99.1 IceCure’s ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA’s Market Authorization Decision ● Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category |
|
| January 27, 2025 |
Exhibit 99.1 IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China Seeks to expand regulatory approval in China where IceSense3 has already been approved CAESAREA, Israel, January 27, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alt |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 13, 2025 |
ICECURE MEDICAL LTD. Up to US$13,960,500 of Ordinary Shares EQUITY DISTRIBUTION AGREEMENT Exhibit 10.1 ICECURE MEDICAL LTD. Up to US$13,960,500 of Ordinary Shares EQUITY DISTRIBUTION AGREEMENT January 13, 2025 Maxim Group LLC 300 Park Avenue New York, New York 10022 Ladies and Gentlemen: This Equity Distribution Agreement (this “Agreement”) is entered into between IceCure Medical Ltd., a company formed under the laws of the State of Israel (the “Company”) and Maxim Group LLC (the “Agen |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 4) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 13, 2025 |
EX-99.1 2 ea022734603ex99-1icecure.htm PRESS RELEASE DATED JANUARY 13, 2025 TITLED "ICECURE MEDICAL CEO ISSUES LETTER TO SHAREHOLDERS & REPORTS INCREASE OF 42% IN PROSENSE SALES FOR 2024 IN NORTH AMERICA." Exhibit 99.1 IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America ● Increase in sales of ProSense®, based on preliminary unaud |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 13, 2025 |
Up to $13,960,500 Ordinary Shares IceCure Medical Ltd. PROSPECTUS SUPPLEMENT (To Prospectus dated September 14, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| January 6, 2025 |
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule Exhibit 99.1 IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule CAESAREA, Israel, January 6, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a notifica |
|
| January 3, 2025 |
Exhibit 99.1 European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology XSense™ system’s innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, January 3, 2025 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Com |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: January 2025 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: December 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| December 5, 2024 |
Exhibit 99.1 IceCure’s ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results ● Data confirm previous results showing that ProSense® cryoablation is highly effective for kidney tumors < 3 cm and a safe procedure for kidney tumors < 5 cm in people ineligible for surgery ● Interim results presented at the Isr |
|
| November 26, 2024 |
EX-99.1 2 ea022263501ex99-1icecure.htm PRESS RELEASE DATED NOVEMBER 26, 2024 TITLED "ICECURE MEDICAL REPORTS 36% SALES GROWTH IN THE FIRST NINE MONTHS OF 2024 DRIVEN BY GLOBAL ADOPTION OF PROSENSE CRYOABLATION" Exhibit 99.1 IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation FDA Marketing Authorization Decision on Early Stag |
|
| November 26, 2024 |
6-K 1 ea0222635-6kicecure.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into Englis |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addres |
|
| November 25, 2024 |
Exhibit 99.1 IceCure’s Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan’s Patent Office Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablation CAESAREA, Israel, November 25, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoa |
|
| November 14, 2024 |
ICCM / IceCure Medical Ltd / Epoch Partner Investments Ltd - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 y1113240sc13ga3.htm AMENDMENT NO. 3 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* IceCure Medical Ltd. (Name of Issuer) Ordinary Shares, no par value (Title of C |
|
| November 8, 2024 |
Exhibit 99.1 FDA Advisory Panel Votes in Favor of IceCure’s ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel, November 8, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology th |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: November 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| November 8, 2024 |
Exhibit 10.10 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [●], 2024, between IceCure Medical Ltd, a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchase |
|
| November 8, 2024 |
ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2024 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| November 8, 2024 |
As filed with the Securities and Exchange Commission on November 8, 2024 As filed with the Securities and Exchange Commission on November 8, 2024 Registration No. |
|
| November 5, 2024 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT , 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Roth Capital Partners, LLC 57 W. 57th St., 18th Fl. New York, NY 10019 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), hereby agrees to sell up |
|
| November 5, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) IceCure Medical Ltd. |
|
| November 5, 2024 |
ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2024 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise |
|
| November 5, 2024 |
Exhibit 10.10 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [●], 2024, between IceCure Medical Ltd, a company formed under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchase |
|
| November 5, 2024 |
Exhibit 10.11 ICECURE MEDICAL LTD. and Vstock Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of , 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2024 (“Agreement”), by and between IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and VStock Transfer, LLC (“VStock” or the “Warrant Agent”). W I T N E S S E T H W |
|
| November 5, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Exhibit 4.2 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ICECURE MEDICAL LTD. Warrant Shares: Date of Issuance: , 2024 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| November 5, 2024 |
As filed with the Securities and Exchange Commission on November 5, 2024 As filed with the Securities and Exchange Commission on November 5, 2024 Registration No. |
|
| October 21, 2024 |
Exhibit 99.1 IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, October 21, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Compa |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| October 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) IceCure Medical Ltd. |
|
| October 15, 2024 |
As filed with the Securities and Exchange Commission on October 15, 2024 As filed with the Securities and Exchange Commission on October 15, 2024 Registration No. |
|
| October 7, 2024 |
Exhibit 99.1 IceCure’s ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference ● ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award ● THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryoablation, radiofrequency, and microwave) win |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: October 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal e |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2024 (Report No. 3) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 24, 2024 |
Exhibit 99.1 IceCure’s ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate ● Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7 |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2024 (Report No. 2) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Addre |
|
| September 16, 2024 |
Exhibit 99.1 Study Published in the British Journal of Radiology Demonstrates IceCure’s ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues ● Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage ● Independent stu |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: September 2024 Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address of principal |
|
| September 12, 2024 |
Exhibit 99.1 IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 ● Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer ● FDA decision regarding marke |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of: August 2024 (Report No. 5) Commission File Number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address |
|
| August 28, 2024 |
Exhibit 99.1 USPTO Grants Notice of Allowance for Additional Patent on IceCure’s Novel Cryogenic Pump Technology: Reinforces IceCure’s Global IP Leadership in Cryoablation Technologies ● Further broadens the uses and applications of IceCure’s cryoablation platform into a wide range of technology fields ● Over 50 patents issued and allowed worldwide for IceCure’s platform cryoablation technology CA |
|
| August 20, 2024 |
Exhibit 99.3 IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 (Report No. 4) Commission file number: 001-40753 ICECURE MEDICAL LTD. (Translation of registrant’s name into English) 7 Ha’Eshel St., PO Box 3163 Caesarea, 3079504 Israel (Address o |
|
| August 20, 2024 |
Exhibit 99.1 ICECURE MEDICAL LTD. UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (U.S. dollars in thousands, except share data and per share data) As of June 30, As of December 31, 2024 2023 ASSETS CURRENT ASSETS Cash and cash equivalents 9,652 10,533 Short-term deposits 807 529 Trade receivables 325 103 Inventory 1,969 2,275 Prepaid expenses and other receivables 574 744 Total current ass |
|
| August 20, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by th |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
